NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

☐ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.

☑ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).

☑ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).

☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."

☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).

☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).

☐ 7. Other _____

Applicant Must Provide:

☑ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".

☐ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.

☑ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216
For CRF Submission Help, call (703) 308-4212
For PatentIn software help, call (703) 308-6856

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE

andervest

PAGE: 1

1644

RAW SEQUENCE LISTING
PATENT APPLICATION   *US/09/027,777B*

DATE: 06/07/1999
TIME: 12:17:23

INPUT SET: S32130.raw

This Raw Listing contains the General
Information Section and up to the first 5 pages.

```
 1                           SEQUENCE LISTING
 2
 3     (1)    General Information:                          ENTERED
 4
 5            (i) APPLICANT: IMMER, Hansueli
 6                          FORSSMANN, Wolf-Georg
 7                          ADERMANN, Knut
 8                          KLESSEN, Christian
 9
10            (ii) TITLE OF INVENTION: PROCESS AND INTERMEDIATE PRODUCTS FOR
11     PREPARING CARDIODILATIN FRAGMENTS AND HIGHLY PURIFIED CARDIODILATIN
12     FRAGMENTS
13
14          (iii) NUMBER OF SEQUENCES: 11
15
16           (iv) CORRESPONDENCE ADDRESS:
17                    (A) ADDRESSEE: Nikaido, Marmelstein, Murray & Oram
18                    (B) STREET: 655 Fifteenth Street, N.W., Suite 330
19                    (C) CITY: Washington
20                    (D) STATE: D.C.
21                    (E) COUNTRY: USA
22                    (F) ZIP: 20005-4810
23
24            (v) COMPUTER READABLE FORM:
25                    (A) MEDIUM TYPE: Floppy disk
26                    (B) COMPUTER: IBM PC compatible
27                    (C) OPERATING SYSTEM: PC-DOS/MS-DOS
28                    (D) SOFTWARE: PatentIn Release #1.0, Version #1.30
29
30           (vi) CURRENT APPLICATION DATA:
31                    (A) APPLICATION NUMBER: US 09/027,777
32                    (B) FILING DATE: 23-FEB-1998
33                    (C) CLASSIFICATION:
34
35          (vii) PRIOR APPLICATION DATA:
36                    (A) APPLICATION NUMBER: DE 44 20 381.0
37                    (B) FILING DATE: 02-JUN-1994
38
39          (vii) PRIOR APPLICATION DATA:
40                    (A) APPLICATION NUMBER: DE 195 13 784.1
41                    (B) FILING DATE: 10-APR-1995
42
43         (viii) ATTORNEY/AGENT INFORMATION:
44                    (A) NAME: Kitts, Monica C.
45                    (B) REGISTRATION NUMBER: 36,105
46                    (C) REFERENCE/DOCKET NUMBER: P1614-8019
```

```
47
48        (ix) TELECOMMUNICATION INFORMATION:
49             (A) TELEPHONE: (202) 638-5000
50             (B) TELEFAX: (202) 368-4810
51
52
53   (2) INFORMATION FOR SEQ ID NO:1:
54
55        (i) SEQUENCE CHARACTERISTICS:
56             (A) LENGTH: 17 amino acids
57             (B) TYPE: amino acid
58             (C) STRANDEDNESS:
59             (D) TOPOLOGY: linear
60
61        (ii) MOLECULE TYPE: peptide
62
63
64
65
66        (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:
67
68        Cys Phe Gly Gly Arg Met Asp Arg Ile Gly Ala Gln Ser Gly Leu Gly
69        1                   5                   10                  15
70
71        Cys
72
73
74   (2) INFORMATION FOR SEQ ID NO:2:
75
76        (i) SEQUENCE CHARACTERISTICS:
77             (A) LENGTH: 15 amino acids
78             (B) TYPE: amino acid
79             (C) STRANDEDNESS:
80             (D) TOPOLOGY: linear
81
82        (ii) MOLECULE TYPE: peptide
83
84
85
86
87        (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:
88
89        Leu Arg Ala Leu Leu Thr Ala Pro Arg Ser Leu Arg Arg Ser Ser
90        1                   5                   10                  15
91
92   (2) INFORMATION FOR SEQ ID NO:3:
93
94        (i) SEQUENCE CHARACTERISTICS:
95             (A) LENGTH: 5 amino acids
96             (B) TYPE: amino acid
97             (C) STRANDEDNESS:
98             (D) TOPOLOGY: linear
99
```

INPUT SET: S32130.raw

```
100          (ii) MOLECULE TYPE: peptide
101
102
103
104
105          (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:
106
107          Asn Ser Phe Arg Tyr
108          1                 5
109
110     (2) INFORMATION FOR SEQ ID NO:4:
111
112          (i) SEQUENCE CHARACTERISTICS:
113               (A) LENGTH: 37 amino acids
114               (B) TYPE: amino acid
115               (C) STRANDEDNESS:
116               (D) TOPOLOGY: linear
117
118          (ii) MOLECULE TYPE: peptide
119
120
121          (ix) FEATURE:
122               (A) NAME/KEY: Peptide
123               (B) LOCATION: 1..15
124               (D) OTHER INFORMATION: /note= "Xaa chain is an amino acid
125     chain of 0 - 15 amino acids."
126
127          (ix) FEATURE:
128               (A) NAME/KEY: Peptide
129               (B) LOCATION: 33..37
130               (D) OTHER INFORMATION: /note= "Xaa chain is an amino acid
131     chain of 0 - 5 amino acids."
132
133          (ix) FEATURE:
134               (A) NAME/KEY: Cross-links
135               (B) LOCATION: 16..32
136
137
138          (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:
139
140          Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys
141          1                   5                   10                  15
142
143          Phe Gly Gly Arg Met Asp Arg Ile Gly Ala Gln Ser Gly Leu Gly Cys
144                       20                  25                  30
145
146          Xaa Xaa Xaa Xaa Xaa
147                  35
148
149     (2) INFORMATION FOR SEQ ID NO:5:
150
151          (i) SEQUENCE CHARACTERISTICS:
152               (A) LENGTH: 32 amino acids
```

PAGE: 4

RAW SEQUENCE LISTING
PATENT APPLICATION   *US/09/027,777B*

DATE: 06/07/1999
TIME: 12:17:24

INPUT SET: S32130.raw

```
153                   (B) TYPE: amino acid
154                   (C) STRANDEDNESS:
155                   (D) TOPOLOGY: linear
156
157            (ii) MOLECULE TYPE: peptide
158
159
160            (ix) FEATURE:
161                   (A) NAME/KEY: Cross-links
162                   (B) LOCATION: 11..27
163
164
165            (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:
166
167            Thr Ala Pro Arg Ser Leu Arg Arg Ser Ser Cys Phe Gly Gly Arg Met
168            1               5                   10                  15
169
170            Asp Arg Ile Gly Ala Gln Ser Gly Leu Gly Cys Asn Ser Phe Arg Tyr
171                            20                  25                  30
172
173
174      (2) INFORMATION FOR SEQ ID NO:6:
175
176            (i) SEQUENCE CHARACTERISTICS:
177                   (A) LENGTH: 14 amino acids
178                   (B) TYPE: amino acid
179                   (C) STRANDEDNESS:
180                   (D) TOPOLOGY: linear
181
182            (ii) MOLECULE TYPE: peptide
183
184
185            (ix) FEATURE:
186                   (A) NAME/KEY: Modified-site
187                   (B) LOCATION: 1
188                   (D) OTHER INFORMATION: /product= "Modified by a Boc protecting
189      group and a tBu protecting group"
190
191            (ix) FEATURE:
192                   (A) NAME/KEY: Modified-site
193                   (B) LOCATION: 4
194                   (D) OTHER INFORMATION: /note= "Modified by a tBu protecting
195      group and a Pbf protecting group"
196
197            (ix) FEATURE:
198                   (A) NAME/KEY: Modified-site
199                   (B) LOCATION: 7
200                   (D) OTHER INFORMATION: /note= "Modified by a Pbf protecting
201      group"
202
203            (ix) FEATURE:
204                   (A) NAME/KEY: Modified-site
205                   (B) LOCATION: 8
```

PAGE: 5

RAW SEQUENCE LISTING
PATENT APPLICATION *US/09/027,777B*

DATE: 06/07/1999
TIME: 12:17:25

INPUT SET: S32130.raw

206   (D) OTHER INFORMATION: /note= "Modified by a Pbf protecting
207   group"
208
209   (ix) FEATURE:
210   (A) NAME/KEY: Modified-site
211   (B) LOCATION: 9
212   (D) OTHER INFORMATION: /note= "Modified by a tBu protecting
213   group"
214
215   (ix) FEATURE:
216   (A) NAME/KEY: Modified-site
217   (B) LOCATION: 10
218   (D) OTHER INFORMATION: /note= "Modified by a tBu protecting
219   group"
220
221   (ix) FEATURE:
222   (A) NAME/KEY: Modified-site
223   (B) LOCATION: 11
224   (D) OTHER INFORMATION: /note= "Modified by a Acm protecting
225   group"
226
227
228   (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:
229
230   Thr Ala Pro Arg Ser Leu Arg Arg Ser Ser Cys Phe Gly Gly
231   1   5   10
232
233   (2) INFORMATION FOR SEQ ID NO:7:
234
235   (i) SEQUENCE CHARACTERISTICS:
236   (A) LENGTH: 12 amino acids
237   (B) TYPE: amino acid
238   (C) STRANDEDNESS:
239   (D) TOPOLOGY: linear
240
241   (ii) MOLECULE TYPE: peptide
242
243
244   (ix) FEATURE:
245   (A) NAME/KEY: Modified-site
246   (B) LOCATION: 1
247   (D) OTHER INFORMATION: /product= "Modified by a Fmoc
248   protecting group and a Pbf protecting group"
249
250   (ix) FEATURE:
251   (A) NAME/KEY: Modified-site
252   (B) LOCATION: 3
253   (D) OTHER INFORMATION: /product= "Modified by a OtBu
254   protecting group"
255
256   (ix) FEATURE:
257   (A) NAME/KEY: Modified-site
258   (B) LOCATION: 4

SEQUENCE VERIFICATION REPORT
PATENT APPLICATION   *US/09/027,777B*

INPUT SET: S32130.raw

Line   Error   Original Text